PE-Backed Biotech Co. UniQure Eyes $75M IPO

Law360, New York (January 2, 2014, 2:59 PM EST) -- Dutch biotech company uniQure plans to make a U.S. public offering to raise up to $75 million in capital, according to U.S. Securities and Exchange Commission filings Thursday.

The IPO filings come less than a year after the company raised €14.1 million ($19.3 million) from private equity investors led by London-based Coller Capital.

Amsterdam-based uniQure developed the first gene therapy medicine approved for use in the Western world, with its fat processing disorder treatment Glybera, which was approved by European Union regulators in 2012.

The company...
To view the full article, register now.